ALXO
- ALX Oncology Holdings Inc.
()
Overview
Company Summary
ALX Oncology Holdings Inc., or ALXO, is a biopharmaceutical company that focuses on developing innovative treatments for cancer. Their main objective is to develop targeted therapies that effectively address the unmet medical needs of cancer patients.
ALXO's approach revolves around harnessing the immune system's potential to fight cancer. They specialize in the development of antibodies that specifically target immune checkpoints, which are proteins that regulate the body's immune response. By blocking or activating these checkpoints, ALXO aims to modulate the immune system to recognize and attack cancer cells more effectively.
The company's lead product candidate is ALX148, an investigational antibody designed to block a checkpoint called CD47. CD47 is a protein expressed on cancer cells that sends a "do not eat me" signal to immune cells, allowing tumors to evade detection and destruction. By blocking CD47, ALX148 aims to enhance the ability of the immune system to recognize and eradicate cancer cells.
ALXO has conducted preclinical and clinical studies to evaluate the safety and efficacy of ALX148 in various types of cancers, including solid tumors and hematological malignancies. Their ultimate goal is to develop ALX148 as a treatment option for cancer patients who do not adequately respond to existing therapies.
In addition to their lead candidate, ALXO also explores the potential of other immune checkpoint blockers and combination therapies. By employing a comprehensive approach that targets multiple aspects of the immune response to cancer, they aim to improve patient outcomes and contribute to the advancement of cancer treatment options.
Overall, ALX Oncology Holdings Inc. is dedicated to researching and developing innovative therapies that leverage the immune system's capabilities to fight cancer, with the hope of providing new treatment options for patients in need.